ATM is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains ATM status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 2 clinical trials for langerhans cell histiocytosis, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 1 (0 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].